Multiple sclerosis

Novel agent slows grey matter atrophy in MS but neuroprotection is not black and white

Ibudilast slows grey matter and whole brain atrophy but has no impact on brain lesion counts in primary or secondary progressive MS, new results from the anti-inflammatory agent show. A secondary analysis of the 2018 SPRINT-MS study, which compared ibudilast with placebo over 96 weeks, found a 35% treatment effect on grey matter atrophy with ...

Already a member?

Login to keep reading.

© 2021 the limbic